Mechanisms and clinical applications of HDAC inhibitors in cancer
10.3760/cma.j.issn.1673-422X.2013.07.006
- VernacularTitle:组蛋白去乙酰化酶抑制剂在肿瘤研究中的机制及临床应用
- Author:
Dandan YU
;
Gang WU
;
Hongli LIU
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Drug therapy;
Histone deacetylases;
Molecular mechanisms of pharmacological action;
Clinical trial
- From:
Journal of International Oncology
2013;40(7):497-500
- CountryChina
- Language:Chinese
-
Abstract:
Acetylation regulated by histone deacetylases (HDAC) has a broad influence on plenty of physiological processes and regulation of malignant tumor.HDAC inhibitors can promote tumor cell apoptosis and have little effect on normal cells,so they have been developed a new kind of anti-tumor agent,and part of them have entered clinical trials.Vorinostat and romidepsin have been approved by FDA for treating cutaneous T cell lymphoma patients with progressive,persistent and recurrent disease.Studies of the molecular mechanisms of the HDAC inhibitors will contribute to the further clinical application.
